BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/22/2026 3:20:35 AM | Browse: 1 | Download: 0
 |
Received |
|
2025-12-18 02:12 |
|
Peer-Review Started |
|
2025-12-18 02:12 |
|
First Decision by Editorial Office Director |
|
2026-01-21 09:22 |
|
Return for Revision |
|
2026-01-21 09:22 |
|
Revised |
|
2026-01-30 16:44 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-05-12 02:41 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-05-12 10:56 |
|
Articles in Press |
|
2026-05-12 10:56 |
|
Edit the Manuscript by Language Editor |
|
2026-05-13 03:02 |
|
Typeset the Manuscript |
|
2026-06-26 03:17 |
|
Publish the Manuscript Online |
|
2026-09-22 03:20 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Opinion Review |
| Article Title |
From the brain to the liver: Pharmacokinetic dilemmas and safety barriers in levodopa-based antifibrotic therapy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Dan-Yu Yin, Xiang-Yi Liu, Ang Li and Zhi-Gang Ren |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
No. 82470654 |
| Natural Science Foundation Key Project of Henan Province |
No. 232300421124 |
| Henan Zhongyuan Medical Science and Technology Innovation and Development Foundation |
No. ZYYC202301ZD |
|
| Corresponding Author |
Zhi-Gang Ren, Department of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, Jianshe East Road, Zhengzhou 450052, Henan Province, China. fccrenzg@zzu.edu.cn |
| Key Words |
Levodopa; Liver fibrosis; Dopamine receptor D1; Drug repurposing; Pharmacokinetic mismatch |
| Core Tip |
There is a lack of approved direct antifibrotic therapies for liver fibrosis. Levodopa has been reported to exert antifibrotic effects by activating hepatic dopamine receptor D1 (DRD1) and suppressing yes-associated protein signaling in hepatic stellate cells. However, its standard Parkinson’s disease regimen includes peripheral aromatic L-amino acid decarboxylase inhibitors, which limit the generation of the hepatic dopamine required for this mechanism. This letter highlights this pharmacokinetic contradiction and additional translational barriers, including receptor nonselectivity, regeneration-related safety concerns, and portal hypertension risk, and proposes liver-targeted or DRD1-selective strategies as more rational alternatives. |
| Publish Date |
2026-09-22 03:20 |
| Citation |
Yin DY, Liu XY, Li A, Ren ZG. From the brain to the liver: Pharmacokinetic dilemmas and safety barriers in levodopa-based antifibrotic therapy. World J Gastroenterol 2026; 32(42): 117873
|
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i42/117873.htm |
| DOI |
https://doi.org/10.3748/wjg.117873 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
